Acute Ischemic Stroke Market Opportunities Analysed & Forecast in In-demand GlobalData Report Available at MarketPublishers.com06 Mar 2014 • by Natalie Aster
LONDON – Through 2017, the acute ischemic stroke (AIS) market is set to undergo certain transformation. Starting from 2015, Activase is likely to see decline in sales, which is mainly attributed to the upcoming launch of Lundbeck’s novel thrombolytic agent desmoteplase that has an extended (9 hours) therapeutic time window for acute revascularization therapy (RT). Other drivers include the impending patent expiration for Activase/Actilyse and the ensuing erosion from potential biosimilars, implementation of telemedicine technology, a booming and aging population, resulting in an upsurge in the incidence rates of strokes.
High attrition rates of late-stage drug development keep on hampering RnD efforts to bring new therapies to market, which means AIS patients are limited by few efficient treatment options. At present, however, the better half of AIS patients are not treated with Activase/Actilyse owing to tough eligibility criteria for thrombolysis treatment together with a narrow (up to 3 hours) therapeutic time window.
In-demand report “OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017” developed by GlobalData provides an in-depth guide to the AIS market. It reviews AIS therapy; presents data on annualised market revenue, treatment usage pattern and annual cost of therapy (from 2012) with forecasts to 2017. The report features market characterisation, unmet needs, clinical trial evaluation and implications for the therapeutics market. It provides a pipeline overview including late-stage pipeline drug analysis as well as an overview of drugs in earlier development phases. The competitive scenario (as of today and in the future) in the global therapeutics market is examined in detail. The study gives insight into the industry’s key growth propellers, limiters and challenges, alongside giving qualitative analysis of the implications of each trend.
OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017
Published: December, 2013
Price: US$ 5,995.00
Other Reports on Rare & Niche Diseases or Diseases with Large Unmet Need Include:
- OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017
and more …
More studies by the publisher can be found at GlobalData page.